Development of novel therapies for gut dysbioses

Borody, Thomas Julius Prof

Development of novel therapies for gut dysbioses

Borody, Thomas Julius Prof

Permalink

Publication Type:: Thesis
Issue Date:: 2016

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download contents and abstractAdobe PDF (225 kB)

Adobe PDF

Download thesisAdobe PDF (6.23 MB)

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Borody, Thomas Julius Prof
dc.date.accessioned	2016-09-21T04:55:02Z
dc.date.available	2016-09-21T04:55:02Z
dc.date.issued	2016
dc.identifier.uri	http://hdl.handle.net/10453/52985
dc.description	University of Technology Sydney. Faculty of Science.	en_AU
dc.description.abstract	This thesis reports results of 30 years of systematic clinical investigations carried out by the author in the general area of “infection-driven inflammation”. The Centre for Digestive Diseases (CDD) endoscopy clinic was founded by the author in 1984 closely coinciding with Drs Barry Marshall and Robin Warren reporting gastric spiral bacteria with pathogenic role in ulcer disease. CDD was able to source gastric biopsies with Helicobacter pylori(HP) from numerous patients with ulcer disease creating the environment necessary for HP research. Hence, Section 1 of the Thesis describes systematic studies which asked questions such as ‘which is the best therapy’, ‘what is the role of acid suppression’ and the ‘role of cigarettes’? This culminated in the development of ‘triple therapy’, the first clinically effective HP cure commercialised later as Helidac. Success in HP research soon led to the treatment of the candidate infective cause of Crohn’s disease called Mycobacterium avium subspecies paratuberculosis (MAP). This comprised of three antibiotics which were active intracellularly - another ‘triple therapy’ akin to HP treatment. However, curing HP could be achieved in 7 days and ulcer healing in 6 weeks whereas MAP – one of the slowest growing bacterial pathogens – required treatment for many months to heal the bowel. So in Section 2 of the Thesis the effect of Anti-MAP therapy on healing Crohn’s disease was studied. Funding from the Broad Foundation supported culture and PCR of MAP while an Israeli company, RedHill Biopharma has funded current pivotal trials with a view to an FDA approval. Section 3 of the Thesis describes research in Faecal Microbiota Transplantation (FMT). FMT was first used at CDD in 1988 in a patient with indeterminate colitis - the first patient world-wide treated for colitis and cured. Generally Clostridium difficile infection (CDI) is treated with FMT at CDD with a cure rate exceeding 95%. Subsequently over 6,000 FMT treatments were carried out and new indications for FMT were discovered, both within and outside of the GI tract. These included ulcerative colitis, irritable bowel syndrome, constipation, MS, arthritis, acne, and others, reported in enclosed publications. CDD work in FMT contributed to the global growth of microbiome research and culminated in the creation of the lyophilised encapsulated FMT. Each of the three Sections has addressed “infection-driven inflammation” in different body regions. It is hoped that reported findings in this Thesis will lead to new therapies that will result in significant clinical improvements.	en_AU
dc.format	Thesis (DSc)
dc.language.iso	en_AU	en_AU
dc.relation	https://opus.lib.uts.edu.au/bitstream/10453/52985/7/02whole.pdf
dc.rights	au.edu.uts.lib/ppc
dc.rights	The author owns the copyright in this thesis including all reproduction and reuse rights for the work. The work may not be altered without the permission of the copyright owner. Attribution is essential when quoting or paraphrasing from this thesis.
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	Ulcer diseases.	en
dc.subject	Gut dysbioses.	en
dc.subject	Gastric spiral bacteria.	en
dc.subject	Helicobacter pylori(HP).	en
dc.subject	Crohn’s disease.	en
dc.subject	Mycobacterium avium subspecies paratuberculosis (MAP).	en
dc.subject	‘Triple therapy’.	en
dc.subject	Anti-MAP therapy.	en
dc.subject	Faecal Microbiota Transplantation (FMT).	en
dc.subject	Clostridium difficile infection (CDI).	en
dc.subject	Lyophilised encapsulated FMT.	en
dc.title	Development of novel therapies for gut dysbioses	en_AU
dc.type	Thesis	en_AU
utslib.copyright.status	open_access

Abstract:

This thesis reports results of 30 years of systematic clinical investigations carried out by the author in the general area of “infection-driven inflammation”. The Centre for Digestive Diseases (CDD) endoscopy clinic was founded by the author in 1984 closely coinciding with Drs Barry Marshall and Robin Warren reporting gastric spiral bacteria with pathogenic role in ulcer disease. CDD was able to source gastric biopsies with Helicobacter pylori(HP) from numerous patients with ulcer disease creating the environment necessary for HP research. Hence, Section 1 of the Thesis describes systematic studies which asked questions such as ‘which is the best therapy’, ‘what is the role of acid suppression’ and the ‘role of cigarettes’? This culminated in the development of ‘triple therapy’, the first clinically effective HP cure commercialised later as Helidac. Success in HP research soon led to the treatment of the candidate infective cause of Crohn’s disease called Mycobacterium avium subspecies paratuberculosis (MAP). This comprised of three antibiotics which were active intracellularly - another ‘triple therapy’ akin to HP treatment. However, curing HP could be achieved in 7 days and ulcer healing in 6 weeks whereas MAP – one of the slowest growing bacterial pathogens – required treatment for many months to heal the bowel. So in Section 2 of the Thesis the effect of Anti-MAP therapy on healing Crohn’s disease was studied. Funding from the Broad Foundation supported culture and PCR of MAP while an Israeli company, RedHill Biopharma has funded current pivotal trials with a view to an FDA approval. Section 3 of the Thesis describes research in Faecal Microbiota Transplantation (FMT). FMT was first used at CDD in 1988 in a patient with indeterminate colitis - the first patient world-wide treated for colitis and cured. Generally Clostridium difficile infection (CDI) is treated with FMT at CDD with a cure rate exceeding 95%. Subsequently over 6,000 FMT treatments were carried out and new indications for FMT were discovered, both within and outside of the GI tract. These included ulcerative colitis, irritable bowel syndrome, constipation, MS, arthritis, acne, and others, reported in enclosed publications. CDD work in FMT contributed to the global growth of microbiome research and culminated in the creation of the lyophilised encapsulated FMT. Each of the three Sections has addressed “infection-driven inflammation” in different body regions. It is hoped that reported findings in this Thesis will lead to new therapies that will result in significant clinical improvements.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/52985